<DOC>
	<DOCNO>NCT02290327</DOCNO>
	<brief_summary>The purpose Pilot Trial determine feasibility conduct large randomize control trial ( RCT ) , aim examine efficacy safety use pantoprazole compare placebo stress ulcer prophylaxis critically ill mechanically ventilated patient ICU .</brief_summary>
	<brief_title>Re-Evaluating Inhibition Stress Erosions : Gastrointestinal Bleeding Prophylaxis In ICU</brief_title>
	<detailed_description>Background For almost 4 decade , stress ulcer prophylaxis prevent upper gastrointestinal ( GI ) bleed standard care ICU . The 1999 American Society Health-System Pharmacists guideline recommend stress ulcer prophylaxis critically ill . The 2013 Surviving Sepsis Campaign guideline recommend stress ulcer prophylaxis patient mechanically ventilate &gt; 48 hour coagulopathy . However , GI bleed rate significantly low today past , potentially reduce optimal resuscitation early enteral nutrition . Additional concern include whether acid suppression impact bleeding , whether acid suppression harm good , give apparent increase risk common , serious problem pneumonia Clostridium difficile infection . Further , prophylaxis become almost universal rather targetted patient risk GI bleeding . Thus , clinician investigator globally call re-evaluation acid suppression large Randomized control trial ( RCT ) compare proton pump inhibitor placebo . Objectives To determine feasibility perform large RCT investigate whether intravenously administer pantoprazole , compare placebo prevents clinically important gastrointestinal bleeding mechanically ventilate patient intensive care unit ( ICU ) , base 3 outcome : inform consent rate ; recruitment rate , protocol adherence Design Prospective , conceal , stratify , randomize , blind , multicentre trial . Setting Canadian Saudi medical-surgical university-affiliated ICUs . Methods Patients stratify center , medical/surgical/trauma status , randomize intervention placebo use allocation ratio 1:1 undisclosed variable block size . Research pharmacists prepare identical 100ml mini-bags pantoprazole 40mg placebo blind research label daily dose . Followup Research Coordinators ICU review patient daily , trial data collect . This involve baseline data ( e.g. , demographic , illness severity , advance life support ) , daily data ( e.g. , study medication administer reason administer ) , relevant medication co-interventions might influence bleeding , ventilator associate pneumonia ( VAP ) Clostridium difficile outcome ( e.g. , enteral nutrition , antibiotic , anticoagulant , possible VAP prevention strategy include probiotic ) , laboratory , microbiology , transfusion radiology documentation help adjudicate outcome clinically important overt bleeding , VAP , Clostridium difficile infection , mortality . We anticipate loss follow ; expect complete follow patient ICU . Patients follow primary secondary outcome ICU stay daily basis . Once patient discharge ICU , long follow daily ; duration hospital stay vital status hospital discharge obtain . A secure web-based central randomization method ensure site-specific stratified allocation table . When patient identify eligible consent obtain Research Coordinator , Research Pharmacist take assignment dispense study drug accordingly . Relevance Results REVISE Pilot Trial provide key feasibility safety data serve plan large multicentre trial pantoprazole versus placebo stress ulcer prophylaxis mechanically ventilate critically ill patient .</detailed_description>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>1 . Adults ≥ 18 year 2 . Anticipated invasive mechanical ventilation ≥48 hour , determine intensivist 1 . Invasive mechanical ventilation &gt; 72 hour randomization . 2 . Patients must receive PPI due active bleeding increase bleeding risk ( e.g. , patient acute GI bleeding , recent severe esophagitis , Zollinger Ellison syndrome , Barrett 's esophagus , peptic ulcer bleed within 8 week [ mild dyspepsia mild gastroesophageal reflex disease exclude ] ) 3 . Receiving dual antiplatelet therapy aspirin clopidogrel prior randomization 4 . Palliative care decision withdraw advance life support ( patient decision forgo cardiopulmonary resuscitation exclude ) 5 . Previous enrolment relate trial 6 . Pregnancy 7 . Physician , patient , substitute decision maker ( SDM ) decline 8 . Two 'daily dos ' prophylaxis H2RA PPI ( one day single PPI dose exclusion criterion daily dose PPI prophylaxis administer ; one day bid [ twice daily ] dose H2RA exclusion criterion twice daily H2RA prophylaxis administer ; one day tid [ thrice daily ] dose H2RA exclusion criterion thrice daily H2RA prophylaxis administer ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Stress ulcer bleeding</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>pneumonia</keyword>
	<keyword>clostridium difficile infection</keyword>
</DOC>